Literature DB >> 23442082

Receptor-based targeting of therapeutics.

Neelesh Kumar Mehra1, Vijay Mishra, Narendra K Jain.   

Abstract

Receptor-based targeting of therapeutics may be a fascinating proposition to improve the therapeutic efficacy of encapsulated drugs. The development of safe and effective nanomedicines is a prerequisite in the current nanotechnological scenario. Currently, the surface engineering of nanocarriers has attracted great attention for targeted therapeutic delivery by selective binding of targeting ligand to the specific receptors present on the surface of cells. In this review, we have discussed the current status of various receptors such as transferrin, lectoferrin, lectin, folate, human EGF receptor, scavenger, nuclear and integrin, which are over-expressed on the surface of cancer cells; along with the relevance of targeted delivery systems such as nanoparticles, polymersomes, dendrimers, liposomes and carbon nanotubes. The review also focuses on the effective utilization of receptor-based targeted delivery systems for the management of cancer in effective ways by minimizing the drug-associated side effects and improving the therapeutic efficacy of developed nano-architectures.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23442082     DOI: 10.4155/tde.13.6

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  17 in total

1.  Self-assembled Targeting of Cancer Cells by Iron(III)-doped, Silica Nanoparticles.

Authors:  K K Pohaku Mitchell; S Sandoval; M J Cortes-Mateos; J G Alfaro; A C Kummel; W C Trogler
Journal:  J Mater Chem B       Date:  2014-12-07       Impact factor: 6.331

Review 2.  Nanotechnology based therapeutic application in cancer diagnosis and therapy.

Authors:  Ragini Singh
Journal:  3 Biotech       Date:  2019-10-23       Impact factor: 2.406

3.  Microdistribution of MC1R-targeted polyplexes in murine melanoma tumor tissue.

Authors:  Mikhail O Durymanov; Tatiana A Slastnikova; Alexey I Kuzmich; Yuri V Khramtsov; Alexey V Ulasov; Andrey A Rosenkranz; Sergey Y Egorov; Eugene D Sverdlov; Alexander S Sobolev
Journal:  Biomaterials       Date:  2013-09-27       Impact factor: 12.479

Review 4.  Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems.

Authors:  Jing-Jun Yan; Jia-Zhi Liao; Ju-Sheng Lin; Xing-Xing He
Journal:  Tumour Biol       Date:  2014-11-26

5.  Fucosylated multiwalled carbon nanotubes for Kupffer cells targeting for the treatment of cytokine-induced liver damage.

Authors:  Richa Gupta; Neelesh Kumar Mehra; Narendra Kumar Jain
Journal:  Pharm Res       Date:  2013-09-17       Impact factor: 4.200

6.  The protective effect of lactoferrin on ventral mesencephalon neurons against MPP + is not connected with its iron binding ability.

Authors:  Jun Wang; Mingxia Bi; Huiying Liu; Ning Song; Junxia Xie
Journal:  Sci Rep       Date:  2015-06-02       Impact factor: 4.379

Review 7.  Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics.

Authors:  Su-Eon Jin; Hyo-Eon Jin; Soon-Sun Hong
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

8.  Heterobivalent agents targeting PSMA and integrin-αvβ3.

Authors:  Hassan M Shallal; Il Minn; Sangeeta R Banerjee; Ala Lisok; Ronnie C Mease; Martin G Pomper
Journal:  Bioconjug Chem       Date:  2014-01-22       Impact factor: 4.774

9.  Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.

Authors:  Srikumar M Raja; Swapnil S Desale; Bhopal Mohapatra; Haitao Luan; Kruti Soni; Jinjin Zhang; Matthew A Storck; Dan Feng; Timothy A Bielecki; Vimla Band; Samuel M Cohen; Tatiana K Bronich; Hamid Band
Journal:  Oncotarget       Date:  2016-03-01

10.  Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).

Authors:  Sonali Kumari; Saad M Ahsan; Jerald M Kumar; Anand K Kondapi; Nalam M Rao
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.